Sugi Predict

Sugi Predict / Compounds / SCHEMBL6011479

SCHEMBL6011479

SCHEMBL6011479

SCCc1cccc(Cl)c1

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ TAAR1 Q96RJ0 3/20 0.63
▸ PNMT P11086 2/20 0.56
▸ HTR3E A5X5Y0 3/20 0.53
▸ HTR3B O95264 3/20 0.53
▸ HTR3A P46098 3/20 0.53
▸ HTR3D Q70Z44 3/20 0.53
▸ HTR3C Q8WXA8 3/20 0.53
▸ AOC3 Q16853 1/20 0.53
▸ CYP3A4 P08684 2/20 0.50
▸ IDO1 P14902 2/20 0.50
▸ AGXT P21549 2/20 0.50
▸ BACE1 P56817 1/20 0.50
▸ CHRM2 P08172 1/20 0.47
▸ CHRM1 P11229 1/20 0.47
▸ CHRM3 P20309 1/20 0.47
▸ C3AR1 Q16581 1/20 0.47
▸ DAO P14920 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12050856 0.85 TAAR1 (0.74) TAAR1PNMTHTR3EHTR3BHTR3A
SCHEMBL332301 0.83 MEN1 (0.48) TAAR1IDO1
SCHEMBL1145832 0.81 — —
SCHEMBL5241228 0.81 TAAR1 (0.68) TAAR1PNMTHTR3EHTR3BHTR3A
SCHEMBL23071686 0.79 TAAR1 (0.65) TAAR1PNMTHTR3EHTR3BHTR3A
SCHEMBL3084324 0.79 TAAR1 (0.65) TAAR1PNMTHTR3EHTR3BHTR3A
SCHEMBL31567921 0.79 TAAR1 (0.65) TAAR1PNMTHTR3EHTR3BHTR3A
SCHEMBL1046229 0.78 TAAR1 (0.59) TAAR1PNMTHTR3EHTR3BHTR3A
SCHEMBL12652039 0.78 TAAR1 (0.62) TAAR1PNMTCYP3A4CHRM2
SCHEMBL148814 0.77 TAAR1 (0.69) TAAR1PNMTHTR3EHTR3BHTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11919921-B2 Galactoside inhibitor of galectins GALECTO BIOTECH AB (DK) 2024-03-05 — — US disclosed
US-20220289783-A1 NOVEL GALACTOSIDE INHIBITOR OF GALECTINS GALECTO BIOTECH AB (DK) 2022-09-15 — — US disclosed
CN-113621005-A alpha-D-galactoside inhibitors of galectins 格莱克特生物技术公司 2021-11-09 — — CN disclosed
CN-107406478-B alpha-D-galactoside inhibitors of galectins 格莱克特生物技术公司 2021-07-27 — — CN disclosed
EP-3828191-A2 NOVEL GALACTOSIDE INHIBITOR OF GALECTINS Galecto Biotech AB (DK) 2021-06-02 — — EP disclosed
EP-3250581-B1 ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS GALECTO BIOTECH AB (DK) 2021-01-20 — — EP disclosed
US-10774102-B2 Galactoside inhibitor of galectins GALECTO BIOTECH AB (DK) 2020-09-15 — — US disclosed
US-20170349619-A1 ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS GALECTO BIOTECH AB (DK) 2017-12-07 — — US disclosed
EP-3250581-A1 ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS Galecto Biotech AB (DK) 2017-12-06 — — EP disclosed
WO-2016120403-A1 ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS GALECTO BIOTECH AB (DK) 2016-08-04 — — WO disclosed
US-6858603-B2 Acetindine derivatives, their preparation and medicaments containing them AVENTIS PHARMA S.A. (FR) 2005-02-22 — — US disclosed
US-20040235816-A1 Azetidine derivatives, their preparation and medicaments containing them AVENTIS PHARMA S.A. (FR) 2004-11-25 — — US disclosed
US-20030162808-A1 Acetindine derivatives, their preparation and medicaments containing them AVENTIS PHARMA S.A. (FR) 2003-08-28 — — US disclosed
EP-0950649-B1 A process for preparing oxyalkylene derivatives in the presence of phosphine oxides MITSUI CHEMICALS INC (JP) 2003-03-26 — — EP disclosed
US-6518264-B2 For treatment/prevention of psychoses, other brain disorders, and cardiovascular disorders AVENTIS PHARMA S.A. (FR) 2003-02-11 — — US disclosed
US-20020035102-A1 Azetidine derivatives, their preparation and medicaments containing them AVENTIS PHARMA S.A. (FR) 2002-03-21 — — US disclosed
US-6130346-A ESTERIFICATION, CARBONATION, SULFONATION, ETHERIFICATION MITSUI CHEMICALS, INC. (JP) 2000-10-10 — — US disclosed
EP-0950649-A1 A process for preparing oxyalkylene derivatives in the presence of phosphine oxides Mitsui Chemicals, Inc. (JP) 1999-10-20 — — EP disclosed
US-5420128-A Pyrimidine derivatives, method of manufacturing the same, and androgen inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1995-05-30 — — US disclosed
EP-0503099-A1 PYRIMIDINE DERIVATIVE, PRODUCTION THEREOF, AND ANDROGEN INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1992-09-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235816-A1 Azetidine derivatives, their preparation and medicaments containing them AZI2, ADRA2A, ADRA2C TAAR1 2608/4885PNMT 1967/4885HTR3E 794/4885
US-11919921-B2 Galactoside inhibitor of galectins LGALS3, LGALS1, LGALS2 TAAR1 3201/4885PNMT 1527/4885HTR3E 792/4885
US-20220289783-A1 NOVEL GALACTOSIDE INHIBITOR OF GALECTINS LGALS1, LGALS3, LGALS2 TAAR1 3271/4885PNMT 2324/4885HTR3E 839/4885
US-20170349619-A1 ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS LGALS3, LGALS1, LGALS2 TAAR1 3465/4885PNMT 2131/4885HTR3E 746/4885
US-10774102-B2 Galactoside inhibitor of galectins LGALS3, LGALS1, LGALS2 TAAR1 3201/4885PNMT 1527/4885HTR3E 792/4885
US-20020035102-A1 Azetidine derivatives, their preparation and medicaments containing them CYP11B2, AZI2, CYP2C19 TAAR1 2844/4885PNMT 1287/4885HTR3E 1387/4885
US-20030162808-A1 Acetindine derivatives, their preparation and medicaments containing them ADRA1D, ADRB2, AZI2 TAAR1 1531/4885PNMT 1942/4885HTR3E 1553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.